IOBT

IO Biotech, Inc.

Investor Moves

NameValueActionChangePriceCurrent Price
Jim SimonsRenaissance Technologies
$-126.4K
ExitQ1 2026
$126k
--
$0.0123
Steven CohenPoint72
$-90.8K
ExitQ4 2025
$91k
--
$0.0123
Jim SimonsRenaissance Technologies
$-72.3K
TrimQ4 2025
$72k
--
$0.0123
Ken GriffinCitadel Advisors
$-40.1K
ExitQ3 2025
$40k
--
$0.0123
Jim SimonsRenaissance Technologies
$5.1K
AddQ3 2025
$5.1k
--
$0.0123
Ken GriffinCitadel Advisors
$-9.5K
TrimQ2 2025
$9.5k
--
$0.0123

Insider Trades

NameValueActionPriceCurrent Price
Hunter HeidiDirector
$21k15k shares
BuyMay 30, 2025
$1.39
$0.0123
Ahmad Qasim IftikharChief Medical Officer
$27k31.4k shares
BuyDec 23, 2024
$0.847
$0.0123
Zocca Mai-BrittDirector, Officer: Chief Executive Officer
$10k12.5k shares
BuyDec 23, 2024
$0.8096
$0.0123
Smith Devin WhittemoreGeneral Counsel
$9.7k12k shares
BuyDec 23, 2024
$0.81
$0.0123
Sullivan AmyChief Financial Officer
$8.5k10.3k shares
BuyDec 23, 2024
$0.8276
$0.0123
Novo Holdings A/S10 Percent Owner
$68k51.5k shares
SellJul 25, 2024
$1.33
$0.0123

News

defenseworld.netIO Biotech, Inc. (NASDAQ:IOBT) Receives Consensus Rating of “Reduce” from Analystsdefenseworld.netApr 18defenseworld.netAnalysts Set IO Biotech, Inc. (NASDAQ:IOBT) PT at $6.33defenseworld.netMar 27